This Week in Virology

TWiV is a weekly netcast about viruses - the kind that make you sick. Brought to you by four university professors and a science writer.


episode 834: COVID-19 clinical update #90 with Dr. Daniel Griffin

In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode
  • Expanded eligibility for booster doses (FDA)
  • More rapid antigen tests approved (FDA)
  • Immune correlates for mRNA-1273 (Science)
  • Risk for still birth with and without COVID-19 (MMWR)
  • PROVENT phase III prophylaxis trial (AstraZenica)
  • Fluvoxamine guidelines (IDSA)
  • COVID-OUT trial (Univ Minnesota)
  • Monoclonal antibody treatment in vaccinated infected (J Inf Dis)
  • Steroid use in non-oxygen requiring patients (QJM)
  • Doxycycline trial (Lancet)
  • Efficacy of inhaled ciclesonide (JAMA)
  • Advise on use of molnupiravir (EMA)
  • Text messaging for monitoring disease (Ann Int Med)
  • Long COVID after vaccination and infection (Res Square)
  • Ivermectin for West Nile virus (Medpage Today)
  • Letters read on TWiV 834
  • Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to


 2021-11-27  41m